To assess the effects of once-weekly exenatide on 24-hour glucose control and variability.
treatment focus on achieving the generally recommended target HbA1c of <7.0%. 3 Although controversial, 4, 5 in the past decade, a body of evidence has implicated glycaemic variability in the pathogenesis of diabetes complications, suggesting that glycaemic variability should also be considered a target for glucose-lowering therapies. 6, 7 Glycaemic variability refers to acute excursions in blood glucose levels, including hypoglycaemic events and postprandial hyperglycaemia, and may be known by some patients and physicians as daily glucose fluctuations. 8 As HbA1c is a measure of overall blood glucose concentrations over 2-3 months, it does not directly reflect the degree of glycaemic variability. 9 Ideally, management of type 2 diabetes should strive for control of HbA1c levels and close approximation of normal diurnal glycaemic variability.
The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide once weekly provides continuous exenatide exposure via gradual release of exenatide from microspheres, thus minimizing peaks and troughs in exenatide concentrations. Once-weekly exenatide has been shown to improve glycaemic control in a glucose-dependent manner, with a low risk of hypoglycaemia, in people with type 2 diabetes. 10 The extended-release delivery method, glucose-dependent effects on insulin and glucagon, 11 and improved postprandial glucose (PPG) control observed with once-weekly exenatide 12 are proposed to lead to less glycaemic variability, although studies specifically designed to evaluate glycaemic variability with once-weekly exenatide treatment have been limited.
In the present study, we investigated the effect of once-weekly exenatide compared with placebo on 24-hour glucose control and glycaemic variability [using data obtained from continuous glucose monitoring (CGM)], and assessed changes in fasting plasma glucose (FPG) and PPG levels in participants with type 2 diabetes on background metformin therapy.
| MATERIALS AND METHODS

| Study design
This was a randomized, double-blind, parallel-group clinical trial conducted from December 2014 to August 2015 across 30 sites in the USA (ClinicalTrials.gov identifier: NCT02288273). The study consisted of a 4-week lead-in period, a 10-week treatment period and a 4-week follow-up for standard safety assessments.
Glucose concentrations were measured every 5 minutes (288 times per day) over 7 days during the final week (baseline) of the 4-week lead-in period and during weeks 4 and 10 using a CGM system (Dexcom G4; Dexcom, San Diego, CA, USA). Glucose values were blinded to both participants and investigators. The CGM sensor was inserted on day −8, day 21 and day 63 at evening time with onsite calibration using an Accu-Chek Aviva Plus glucose meter (Roche, Basel, Switzerland). Participants were instructed to calibrate the CGM system device according to the manufacturer's instructions every 12 hours. Changes from baseline in CGM measures were assessed on day 6 (AE1 day) of weeks 4 and 10, which was the last full day before administration of the next dose of study drug (day 7 of each week).
Thus, CGM assessments aligned with any potential trough in exenatide concentration, if one were to occur.
We measured FPG and HbA1c levels at screening, on day −7 (week −1 during lead-in; FPG only), at randomization (day 1; week 1), and on days 15 (week 3), 22 (week 4), 57 (week 9), 64 (week 10) and 70 (week 10).
Standardized meal tests were conducted on day −7 (week −1), day 22 (week 4) and day 64 (week 10). Participants consumed (within 30 minutes) a standardized breakfast meal accounting for 35% of the daily calorie intake (620-700 kcal; Table S1 , File S1).
Blood samples for glucose and insulin were collected before the breakfast meal and at 30, 60, 120 and 180 minutes after the breakfast meal.
Exenatide concentration was measured on days 1 (week 1), 15 (week 3), 22 (week 4; prior to the meal), 57 (week 9), 64 (week 10; prior to the meal) and 70 (week 10).
| Participants
The study included people with type 2 diabetes aged 18-75 years with HbA1c levels between 7.0% and 10.0% (53 and 86 mmol/mol) and a body mass index of ≤45 kg/m 2 . Participants were on a stable dose of metformin (≥1500 mg/d) for at least 8 weeks before study start, and no other glucose-lowering medications were permitted (File S1). Participants who felt that they were unable to use the CGM device during the lead-in period were encouraged to withdraw before randomization, as CGM was the primary tool used to measure glycaemic variability. Participants provided written informed consent, and the protocol was approved by the institutional review board at each site. The trial was conducted in accordance with the International Conference on Harmonisation guidelines.
| Treatment
At the lead-in visit, the participant's current dietary and exercise behaviour were reviewed. Participants were instructed on medical nutrition in accordance with the American Diabetes Association guidelines or locally accepted guidelines. During the 4-week lead-in period, participants were treated with metformin extended release 1500 or 2000 mg (depending on their dose at screening) once daily with their evening meal. After the lead-in period, participants were randomized with a computer-generated random sequence using an interactive voice/web response system. Participants were randomized 1:1 using a blocked randomization schedule to receive either once-weekly exena- 
| Hypotheses and outcome measures
The primary hypothesis was that once-weekly exenatide on a background of metformin and diet/exercise would lead to significant reductions in 24-hour mean glucose level from baseline to weeks 
| Exenatide pharmacokinetic measurements
Pharmacokinetic samples were analysed by Covance (West Trenton, NJ, USA) using a bioanalytical method, and exenatide concentrations were summarized descriptively. 
| Safety
| Statistical analysis
A modified intention-to-treat (ITT) model was used to analyse all outcomes. The modified ITT population consisted of all randomized participants who received at least one dose of study drug. Categorical variables were summarized by frequency and percentages; continuous variables were summarized by descriptive statistics.
The sample size of 110 participants (55 per treatment group), with an assumed dropout rate of 30%, gave a minimum of 39 participants per treatment. This number provided 90% power to detect a difference in the change in 24-hour mean glucose of 1.00 mmol/L, assuming an s.d. of 1.33 mmol/L, at week 4 between once-weekly exenatide and placebo, and >90% power for the week 10 treatment comparison.
A sequential testing procedure was implemented to control the family-wise type I error. Endpoints were assessed for superiority of once-weekly exenatide versus placebo. In the hierarchical testing order, the primary endpoint of 24-hour mean glucose level at week 10 was tested first, followed by 24-hour mean glucose level at week For CGM-derived variables, 24-hour glucose profiles with <260 of 288 measurements were censored, as an incomplete profile could lead to bias. For profiles with >260 but <288 measurements, missing values were imputed by cubic spine interpolation, or linear interpolation when the number of data points around the missing data was inadequate to support a cubic spine. An exploratory outcome was the comparison between the adjusted mean 24-hour glucose curves using CGM profiles at week 10, based on maximum amplitude of deviation from zero (MADz).
| Analysis of the primary outcome
| Analysis of secondary and exploratory outcomes
Fourier coefficients for individual participant CGM data from each 24-hour period were derived using 24 hours as the longest cycle and aggregated for each protocol period. 14 The data were then aggregated across the whole treatment group for that period, resulting in a defined group function for each period by treatment, from which changes from baseline and treatment difference functions were derived. To control for multiplicity, a bootstrap was performed to define the 95% confidence bounds of the MADz by time point.
| RESULTS
| Participants
A total of 150 participants were screened and entered the lead-in period, and 117 participants were randomized [once-weekly exenatide + metformin (n = 61); placebo + metformin (n = 56); Figure S1, File S1]. One participant randomized in the once-weekly exenatide group was not treated or analysed because of pregnancy, so the modified ITT population included 116 participants. In the once-weekly exenatide and placebo groups, 8/61 (13.1%) and 8/56 (14.3%) participants, respectively, discontinued the study, and 53/61 (86.9%) and 48/56 (85.7%) completed the trial. Baseline characteristics and demographics of the modified ITT population were generally well matched between groups (Table 1 ). Figure 1A ).
| Outcome measures
| Primary outcome
| Secondary and exploratory outcomes
Once-weekly exenatide reduced mean glucose over 24 hours compared with placebo at weeks 4 and 10 ( Figure S2 , File S1). At week 10, treatment differences in changes from baseline in 24-hour glucose cycles were significant beginning at approximately 09:00 hours and remained significant throughout most of the day and early evening, as shown by MADz ( Figure 1B) .
Once-weekly exenatide significantly reduced FPG level compared with placebo at week 4 (placebo-adjusted difference: 
| Exenatide pharmacokinetics
In participants treated with once-weekly exenatide, the mean AE s.d.
exenatide concentration was 62 AE 70 ng/L at the start of week 4, and a steady-state concentration was reached at approximately week 8 ( Figure S3 , File S1). At study end, the mean AE s.d. exenatide concentration was 255 AE 155 ng/L.
| Safety
There were no clinically meaningful changes in clinical laboratory variables, vital signs, ECG results or physical examination findings. Participants had reductions in body weight in both groups over 10 weeks (mean AE s.d reduction: −1.1 AE 2.1 kg and −0.5 AE 1.9 kg in the onceweekly exenatide and placebo groups, respectively).
The most common AEs reported were injection-site nodule (once-weekly exenatide, 10.0% and placebo, 0.0%), urinary tract infection (6.7% and 8.9%), and nausea (6.7% and 0.0%; Table 2 ). Most
AEs were mild to moderate in nature. All serious AEs were considered by the investigator to be unrelated to treatment. These were allowing the continuous release of exenatide with once-weekly therapy. 15 Weekly exenatide administration led to clinically significant improvements in glycaemic control that were evident by week 4, and steady-state concentration of exenatide at approximately week 8 was consistent with previous studies. [16] [17] [18] [19] 
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